Funding Announcements

"We want to build the platform that will make personalised medicine a reality"

"After several years of research in collaboration with Mogrify, it is great to see our transdifferentiated cartilage cells gain commercial traction from grants such as the SBRI Healthcare and (pre-)clinical partners."

"We are pleased to welcome both o2h Ventures Therapeutics Fund as a new shareholder and Sunil Shah, Managing Partner of o2h Ventures Ltd as an observer on the Metrion board."

"This Series B financing allows us to commercialize our lead product in patients with advanced lung cancer, following our positive reimbursement decision. We also have an exciting portfolio of future products that will be advanced in parallel to maximize the benefits of our industry-leading InVision Liquid Biopsy platform to patients. We are grateful to our existing investors for their continued support and are delighted to welcome RT Ventures to our already strong investor base. With these funds in place, we look forward to continuing our mission to transform the lives of cancer patients through the power of liquid biopsy."

"This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering. Through our continued investment in automation and optimising our commercialisation strategy, we aim to maximise shareholder value and exceed our ambitious growth targets. Throughout our journey, Mercia’s investment model has been pivotal to Oxford Genetics’ current success. The ability to leverage capital and continued support from Mercia via seed stage through to later investment rounds has enabled us to attract excellent syndicate investors onto our share register. We are excited to welcome Canaccord Genuity onto our share register alongside Invesco Asset Management and look forward to working with all of our investors to grow the business over the coming years."